 "The question for the FDA is whether there should be a general warning, particularly for patients who are at high risk of cardiovascular disease," the doctor said. "
to the risk of heart attack or stroke," he said in an interview. "
 It was not stopped earlier because trial results did not find increased risk in the first 18 months of the trial, the FDA said.
I think it's good we are looking at safety," Wilson said. "
